OncoMatch

OncoMatch/Clinical Trials/NCT05296681

Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery

Is NCT05296681 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies NBT-NM108 for metastatic colon carcinoma.

Phase 2RecruitingHoward S. Hochster, MDNCT05296681Data as of May 2026

Treatment: NBT-NM108This phase II trial tests whether NBT-NM108 works in reducing chemotherapy-induced diarrhea in patients with colon cancer that has spread to other places in the body (metastatic). Irinotecan is one of the most used medicine for colon cancer, but it leads to diarrhea in most patients receiving it and among some of them, severe diarrhea can occur. NBT-NM108 is a high dietary fiber formula that is developed based on research findings that have shown that high fiber diets can help maintain healthy bacteria in the gut and improve gut function. Giving NBT-NM108 to patients with colon cancer receiving chemotherapy may help relieve or lessen diarrhea symptoms and lead to improved tolerance of the chemotherapy drug, irinotecan.

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Biomarker criteria

Required: UGT1A1 wild-type

Disease stage

Required: Stage IV, IVA, IVB, IVC

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Must have received: irinotecan-based chemotherapy (irinotecan) — second-line or later

Candidate for Second-line or later line therapy with irinotecan-based chemotherapy regimen with starting dose of irinotecan at 180 mg/m2 q2w

Lab requirements

Blood counts

Absolute Neutrophil Count (ANC) >1500/uL

Kidney function

Creatinine < 1.5 x Upper Limit of Normal (ULN)

Liver function

Transaminases < 5x ULN; Bilirubin < 1.5 x ULN; Albumin > 3.0 g/dL

Lab values as acceptable for trials: Absolute Neutrophil Count( ANC) >1500/uL; Creatinine < 1.5 x Upper Limit of Normal (ULN); Transaminases < 5x ULN; Bilirubin < 1.5 x ULN; Albumin > 3.0 g/dL

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Robert Wood Johnson University Hospital, Hamilton · Hamilton, New Jersey
  • Monmouth Medical Center · Lakewood, New Jersey
  • RWJBarnabas Health - Monmouth Medical Center Southern Campus · Lakewood, New Jersey
  • Cooperman Barnabas Medical Center · Livingston, New Jersey
  • Robert Wood Johnson University Hospital · New Brunswick, New Jersey

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify